# LACunar Intervention (LACI-2) Trial-2

> **NCT03451591** · PHASE2,PHASE3 · COMPLETED · sponsor: **University of Edinburgh** · enrollment: 363 (actual)

## Conditions studied

- Cerebral Small Vessel Diseases
- Stroke, Lacunar

## Interventions

- **DRUG:** Isosorbide Mononitrate XL (ISMN)
- **DRUG:** Cilostazol
- **DRUG:** ISMN XL and Cilostazol
- **OTHER:** Neither ISMN nor cilostazol

## Key facts

- **NCT ID:** NCT03451591
- **Lead sponsor:** University of Edinburgh
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-08
- **Primary completion:** 2022-05-31
- **Final completion:** 2022-08-11
- **Target enrollment:** 363 (ACTUAL)
- **Last updated:** 2024-11-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03451591

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03451591, "LACunar Intervention (LACI-2) Trial-2". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03451591. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*